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After the European Group for the Immunological Classification of Leukemia (EGIL) first publlished its definition of biphenotypic acute 
leukemia (BAL) in 1995,1 BAL was recognized as a 
distinct entity by the 2001 World Health Organization 
(WHO) classification of hematopoietic tumors.2 
Whereas colexpression of markers of different lineages 
in acute leukemia (AL) is quite common (the incidence 
of acute myeloid leukemia (AML) colexpressing lyml
phoid markers and acute lymphoblastic leukemia (ALL) 
colexpressing myeloid markers ranges from 5% to 50% 
and 10% to 30%, respectively),3 BAL is diagnosed infrel
quently and accounts for 4% to 5% of all cases of AL.2 
The EGIL definition is immunophenotype based and 
takes into account the number and the degree of specil
ficity of myeloid or lymphoid antigens expressed by 
leukemia blasts.1,2 Consequently, four patterns of colexl
pression can be identified: myeloid + Bllymphoid, myl
eloid + Tllymphoid, trinlineage (myeloid + B+Tl lyml
phoid) and B+Tllymphoid, out of which the latter two 
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BACKGROUnD: biphenotypic acute leukemia (bal) is a distinct entity that is immunophenotypically defined 
by the european Group for the immunological classification of leukemia (eGil) scoring system and accounts 
for less than 5% of all acute leukemia cases. since it is a rare and heterogeneous form of acute leukemia with an 
allegedly poor outcome, there is no consensus on the best treatment approach in these patients. our objective 
was to analyze the biological features and outcome of patients diagnosed with bal in our institution. 
PATIenTS AnD MeThODS: using the eGil system, we identified 21 cases (3.9%) of bal from 535 newly diag-
nosed acute leukemia patients in an 11-year period. 
ReSULTS: there were ten cases of myeloid+b-lymphoid leukemia, eight cases of myeloid+t-lymphoid, one case 
of b+t-lymphoid and two cases of trilineage (myeloid+b+t-lymphoid leukemia). the complete remission (cr) 
rate with high-dose chemotherapy was 72% and overall survival at 5 years was 21%. patients that received acute 
lymphoblastic leukemia-oriented chemotherapy had a higher cr rate compared with those who received acute 
myeloid leukemia-oriented chemotherapy (100% vs. 60%, P=.007). the white blood cell count at diagnosis was 
found to have statistically significant impact on survival. 
COnCLUSIOn: despite the progress in the treatment of acute leukemia, the prognosis of bal remains poor and 
treatment protocols devised explicitly for this entity should be investigated in prospective collaborative studies.
are found extremely rarely. The cell of origin is assumed 
to be the multipotent progenitorlcell with the capabill
ity of differentiating along both myeloid and lymphoid 
lineages.2 Subsequently, according to the FAB classifical
tion, BAL blasts can resemble lymphoblasts (L1 or L2 
morphology) or can be classified as AML on the basis of 
standard morphology and cytochemistry (M1, M2, M4, 
M5 subtypes).4 On cytogenetic analysis, there is a high 
incidence of the Philadelphia (Ph) chromosome, rearl
rangements involving 11q23 and complex abnormalil
ties,5,6 but so far no distinct karyotypic abnormality has 
been reported of being associated exclusively with BAL 
except trisomy 4 which is mostly associated with BAL.7 
BAL affects both adults and children, and although 
more than ten years have elapsed since the EGIL publ
lication on its definition, there is still no consensus on 
the most appropriate treatment of these patients. The 
choice of chemotherapy is either morphologylbased, 
or frequently treatment schemes for ALL are used.8,9 
There have also been attempts on the use of combined 
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treatment schemes.10 So far, the treatment outcome of 
BAL has been considered to be poor, but lately a numl
ber of different reports has been published.5,9,11
The aim of this study was to review the clinical data 
with relation to the outcome in the cohort of BAL pal
tients treated in our center. 
PATIenTS AnD MeThODS
We reviewed the clinical and laboratory data for adult 
patients treated for newly diagnosed acute leukemia at 
the Zagreb Clinical Hospital Center (Croatia) between 
December 1995 and December 2006. Out of 535 AL 
patients, 21 patients (3.9%) were classified as BAL acl
cording to the EGIL criteria.
The AL diagnosis was established using the FAB cril
teria and revised according to the WHO classification. 
The immunophenotype was assessed with a standard 
procedure according to EGIL.1 Cytogenetic analysis 
(Glbanding) was successful in 15 patients and FISH 
analysis using Abbott Vysis LSI Bcr/abl and MLL, 
11q23 probes was performed in 5 and 11 patients, rel
spectively. 
Following lysis of red blood cells, bone marrow white 
blood cells were immunophenotyped by using a panel of 
monoclonal antibodies (Mo.Abs.) and flow cytometry 
(FACScan and FACSCalibur, BD Biosciences, USA). 
The following Mo.Abs. conjugated with FITC, (R)PE, 
RPlCY5, PerCP and APC were used in double, triple 
and recently quadruple staining procedures: CD1a, 
CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, 
CD13, CD14, CD15, CD16, CD19, CD20, CD22, 
CD33, CD34, CD41, CD45, CD56, CD64, CD65w, 
CD71, CD79a, clkit/CD117, antilglycophorin A, 
antilMPO, antilTdt, antillyzozyme and antilHLA DR. 
MoAbs were purchased from the three major sources: 
DAKO, Denmark, BD Biosciences, USA and Caltag, 
USA. The myeloid or B/T lymphoid markers were conl
sidered to be positive if they were expressed in >20% 
of blasts; myeloperoxidase was considered positive if 
expression was found in >10% of blasts.
Treatment 
The patients who met the inclusion criteria were treated 
with intensive chemotherapy+stem cell transplantation 
(SCT) according to the European Organisation for 
Research and Treatment of Cancer (EORTC) protol
cols for the treatment of acute leukemias. Patients were 
classified according to cytomorphology as AML or 
ALL and received induction therapy and postremission 
therapy according to EORTC (AML10lfour patients, 
AML12lfour patients and ALL4lten patients).12l14 The 
three patients with advanced age and Karnofsky score 
<70% received lowldose chemotherapy. All the patients 
were assigned to allogeneic or autologous SCT, accordl
ing to the availability of an HLAlidentical related dol
nor. Consequently, seven patients received autologous 
SCT in first remission, one patient received matched 
unrelated donor (MUD) SCT in second remission and 
none of the patients received a sibling allograft. All of 
the protocols were in accordance with the 1975 Helsinki 
Declaration and approved by the ethical committee of 
our institution according to the national legislation. 
Informed consent was obtained from all patients.
Outcome analysis
Outcome was assessed for patients that received intenl
sive chemotherapy. The diseaselfree survival (DFS) was 
calculated from the date of complete remission (CR) 
until the date of first relapse or death in first CR. The 
duration of survival was calculated from the date of dil
agnosis until the date of death. The followlup was asl
sessed from the date of the diagnosis to the date of the 
last checklup. We tested the impact of the following 
parameters on CR achievement and/or survival: age (< 
or > median value), WBC count (< or > median value), 
FAB (ALL vs. AML) and BAL (myeloid+Bllymphoid 
vs. myeloid+Tllymphoid), subtype AMLloriented vs. 
ALLloriented chemotherapy, autologous SCT vs. chel
motherapy. Single factors were investigated for their 
impact on CR rate by the Fisher’s exact test. Survival 
curves were calculated according to the KaplanlMeier 
technique and twoltailed loglrank test was used to test 
the difference between the survival curves. A P value 
<.05 was considered statistically significant. For statisl
tical analysis SPSS 15 software was used (SPSS Inc., 
USA). 
ReSULTS
The patient and disease characteristics, treatment 
and outcome are listed in Tables 1 and 2 and suml
marized in Table 3.The median age of the patients at 
diagnosis was 44 years (range, 16l74) with a male to 
female ratio 3:1. The median white blood cell (WBC) 
count, hemoglobin concentration and platelet count 
were 14.2×109/L (range, 0.9l296), 101 g/L (range, 
47l149) and 49.5×109/L (range, 7l285), respectively. 
Morphological assessment showed myeloid features in 
nine, lymphoid features in six and undifferentiated in 
six patients. Glbanding was successful in 15 patients. 
Normal cytogenetic findings were present in four pal
tients, numeric changes in five patients and structural 
changes in five patients, while one patient had a coml
plex karyotype; Philadelphia chromosome was identil
fied in 4/20 patients. Abnormalities involving the MLL 
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Table 2. Treatment regimens and outcome.
Patient Treatment Typea CR SCT Outcome
1 lD Na No Dead at 2.4 mo., aD
2 all yes auto Dead at 51.8 mo., aD
3 aml yes auto alive at 14.2 mo., 1CR
4 aml yesb auto Dead at 30.3 mo., aD
5 lD Na No Dead at 7.1 mo., aD
6 all yes auto Dead at 8.3 mo., aD
7 aml No No Dead at 1.6 mo., aD
8 aml No No Dead at 2.9 mo., aD
9 aml No No Dead at 1 mo., aD
10 aml yes No Dead at 1.3 mo. 1CR
11 all yes No Dead at 6.4 mo., aD
12 all yes auto alive at 108 mo., 1CR
13 all yes auto alive at 74.4 mo, 2CR
14 all yes No aliv at 101,7 mo., 1CR
15 all yes muDc Dead at 25.7 mo., aD
16 aml yes auto Dead at 33.7 mo., aD
17 all yes No Dead at 14.1mo., aD
18 aml No No Dead at 22.3 mo., aD
19 lD Na No Dead at 3 mo., aD
20 aml yes No alive at 12.4 mo., 1Rl
21 all yes No Dead at 2.1 mo., aD
lD: low dose; CR: complete remission; SCT: stem cell transplantation; muD: matched unrelated donor; mo.: months; 
aD: active disease; Rl: relapse; alow dose or induction treatment according to the eORTC aml10, aml12 or all 4 
protocols;11,12,13 bafter 3 cycles of chemotherapy; cin second remission.
gene were negative in all of the eleven patients tested 
for them. 
According to the EGIL classification, there were 
ten cases of myeloid+Bllymphoid leukemia (47, 6%), 
eight cases of myeloid+Tllymphoid (38, 1%), one case 
of B+Tllymphoid (4, 8%) and two cases of trilineage 
myeloid+B+Tllymphoid leukemia (9, 5%). The most 
common phenotypic feature was the expression of 
CD34 antigen which was positive in 20/21 patients. 
CR achievement rate was 72% with firstlline highl
dose chemotherapy and the median followlup is 74.4 
months (range, 12.4l108.1). Median diseaselfree surl
vival was 21.2 months (95% CI, 1.5l41.3) and the overl
all survival probability at 2 and 5 years 48% and 21%, rel
spectively. Five patients are alive–three in first complete 
remission (CR), one in second CR, and one in first rel
lapse; sixteen patients died l fifteen due to active disease 
and one from toxicity. Patients that received ALLltail
lored chemotherapy had a better CR achievement rate 
(100%) over the patients that received AMLltailored 
chemotherapy (60%) (P=.007) (Table 3), but there 
was no difference in survival. Out of all the parameters 
tested for their impact on survival, only WBC count < 
or > 14×109/L (median) was found to have statistically 
significant impact (P=.036) (Figure 1). Fisher’s exact 
test was used to test the difference in types of chemol
therapy and phenotype subtypes (myeloid+Bllymphoid 
vs. myeloid+Tllymphoid) between the groups with low 
and high WBC counts. Although more patients rel
ceived ALLltailored chemotherapy in the group with 
WBC count <14×109/L (70 vs. 25%), the two groups 
did not differ significantly in their distribution accordl
ing to the choice of chemotherapy (P=.1534) or phenol
type subtypes (P=.2867). Also, there was no difference 
in CR rates or survival between the patients classified 
as ALL or AML, nor between the two subtypes of 
BALlmyeloid+Bllymphoid vs. myeloid+Tllymphoid 
subtype. There was no advantage in survival in patients 
who underwent autologous SCT.
DISCUSSIOn 
BAL is a rare form of acute leukemia recognized by the 
WHO classification of hematologic malignancies.2 Its 
definition is based on immunophenotyping, and EGIL 
scoring system is used to distinguish BAL from other 
leukemia that colexpress markers from different linl
eages.1 Studies attempting further molecular stratifical
tion of BAL have also been performed,15 one of them 
being the analysis earlier performed in our institution, 
in which immunoglobulin heavy chain (IgH) and Tlcell 
receptor γ (TCRγ) gene rearrangements were found to 
correlate well with lymphoid BAL morphology, whereas 
Figure 1. Overall survival and survival according to WBC <14×109/
l and >14×109/l for Bal patients.
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Table 3. patients and disease characteristics (n=21).
m/F ratio 16/5
age (years), median (range) 44 (16-74)
laboratory values median (range)
Bone marrow blasts (%) 82 (34-95)
WBC (×109/l) 14,2 (0,9-296)
Hgb (g/l) 101 (47-149)
plt (×109/l) 149.5 (7-285)
FaB n
all 6
aml 9
undifferentiated 6
immunophenotype
   B+my 10
   T+my 8
   B+T+iy 1
   B+T+my 2 
Karyotype (n=15)a
   Normal 4
   Numeric changes 5
   Structural changes 5
   Complex changes 1
   philadelphia chromosomeb 4 
Chemotherapy protocols
   aml-tailored 8
   all-tailored 10
   low-dose chemo. 3 
   CR achieved with int. chemo. 13 (72%)
SCT  
   autologous 7 
   allogeneic (muD) 1
Survival median (95%Ci)
DFS (months) 21.2 (1.5-41.3)
OS at 2 and 5 years 48 and 21%
muD: matched unrelated donor; DFS: disease-free survival; OS: overall survival;  
aNumber of patients in which conventional cytogenetics was successfully done; 
bG-banding or FiSH. 
cyclin A1 (CycA1) expression correlated with myeloid 
and undifferentiated morphology of BAL.16 Being a 
rare entity, it is of no surprise that the publications conl
cerning BAL mostly involve singlelcenter experiences 
or caselreports and the recently published study on 43 
BAL patients by the Korean Society of Hematology 
AML/MDS working party is among the ones with the 
highest number of patients.17 The reported patient outl
comes range from 8.1% at four years to close to 60% at 
five years.5,8,9,11,17 So far, no treatment has been designed 
uniquely for BAL and attempts in improving the outl
come are being made also by implementation of novel 
drugs, such as nelarabine for BAL patients with T cell 
markers.18 
The incidence of BAL diagnosed in our Center 
(3.9%) corresponds to the literature data, as well as 
the distribution of patients within the four subtypesl
myeloid+Bllymphoid and myeloid+Tllymphoid being 
the most frequent. The high frequency of CD34 exl
pression and the diverse cytologic findings support the 
suggestion that BAL arises in a multipotent progenitorl
cell. The cytogenetic findings were miscellaneous and 
Ph chromosome was positive in 4 out of 20 patients, 
which is lower than previously reported (30l35%).5,6 
11q23 abnormalities were observed in none of the elevl
en patients tested, contrary to what would be expected. 
Treatment decisions in this group of patients were 
mainly based on cytology and ALLldesigned treatment 
had an advantage in the achievement of CR without the 
advantage in survival, as was already reported by Aribi 
et al.9 The low rate of allogeneic SCT is attributable to 
the fact that patients lacked sibling donors. The overall 
survival was poor with only 21% of patients surviving 
5 years. 
According to the literature, unfavorable prognostic 
findings are age and the occurrence of the abnormalil
ties involving 11q23 or the Ph chromosome,5 to which 
the WBC count has been added lately.9 This was conl
firmed in our study, where patients with a WBC count 
>14×109/L had shorter overall survival than patients 
with lower WBC counts. The three Phlpositive patients 
in our study did have a poor outcome with OS ranging 
from 1.6l25.7 months, but due to a small number no 
definite conclusions can be made about the prognostic 
impact of the Ph chromosome. The Korean group idenl
tified myeloid+Tllymphoid phenotype as having a bad 
prognostic impact and was first in suggesting that iml
munophenotype in BAL has prognostic implications.17 
Our failure to identify any differences in outcome bel
tween the four BAL subtypes can possibly be attribl
uted to the smaller number of patients analyzed. 
Based on our results, as well as the early reports on 
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BAL, one would assume that the prognosis of BAL 
remains poor; however, two recently published papers 
report different conclusions. In the above mentioned 
study by Aribi et al, the overall survival probability at 
five years was reported to be close to 60%. Still, the 
Ph chromosome positive patients, which would be 
considered highlrisk, were excluded from the study. 
Additionally, only one fourth of the patients met the 
EGIL criteria, and for the rest the criteria according 
to which a somewhat lower score was needed to conl
sider a lineage involved were used. Nevertheless, there 
was no difference in survival between the two groups 
of patients.9 In the article by Lee et al a five year overl
all survival of 54% was reported. However, the analysis 
was done on only eight patients with median follow up 
of 10.5 months. Also, in none of the patients the EGIL 
criteria were fully met.11
In conclusion, BAL patients should be regarded as 
highlrisk. In adittion, we have confirmed that a higher 
WBC count is an adverse prognostic feature. Since 
current treatment approach is heterogeneous and ofl
ten based on cytomorphology, treatment protocols del
signed specifically for this type of leukemia should be 
devised, bearing in mind that ALLldesigned protocols 
may have a better response rate. The role of allogeneic 
SCT, including MUD, especially for patients with adl
verse prognostic features should be established. The 
use of novel drugs, such as nelarabine for BAL patients 
with T cell markers or tyrosine kinase inhibitors for Ph 
positive BAL patients should also be addressed. 
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